Search

Seroprevalence of Hospital Staff in Province with Zero COVID-19 cases

Authors

Tanawin Nopsopon, Krit Pongpirul, Korn Chotirosniramit, Wutichai Jakaew, Chuenkhwan Kaewwijit, Sawan Kanchana, Narin Hiransuthikul

BACKGROUND

COVID-19 seroprevalence data has been scarce, especially in less developed countries with a relatively low infection rate.

METHODS

A locally developed rapid IgM/IgG test kit was used for screening hospital staff in Ranong hospital which located in a province with zero COVID-19 prevalence in Thailand from April 17 to May 17, 2020. A total of 844 participants were tested; 82 of which were tested twice with one month apart. (Thai Clinical Trials Registry: TCTR20200426002)

RESULTS

Overall, 0.8% of the participants (7 of 844) had positive immunoglobulin M (IgM), none had positive immunoglobulin G (IgG). Female staffs seemed to have higher IgM seropositive than male staffs (1.0% vs. 0.5%). None of the participants with a history of travel to the high-risk area or a history of close contact with PCR-confirmed COVID-19 case had developed antibodies against SARS-CoV-2. Among 844 staff, 811 had no symptom and six of them developed IgM seropositive (0.7%) while 33 had minor symptoms and only one of them developed IgM seropositive (3.0%). No association between IgM antibody against SARS-CoV-2 status and gender, history of travel to a high-risk area, history of close contact with PCR-confirmed COVID-19 case, history of close contact with suspected COVID-19 case, presence of symptoms within 14 days, or previous PCR status was found. None of the hospital staff developed IgG against SARS-CoV-2.

CONCLUSION

COVID-19 antibody test could detect a substantial number of hospital staffs who could be potential silent spreaders in a province with zero COVID-19 case. Antibody testing should be encouraged for mass screening, especially in asymptomatic healthcare workers.

https://medrxiv.org/cgi/content/short/2020.07.13.20151944.full.pdf

Overview of SARS-COV-2 studies seroprevalence in context of the worldwide  COVID-19 pandemie. You can register a study here: Contribute

serohub@helmholtz-hzi.de
@serohub on Twitter
hzi-braunschweig/serohub on GitHub